2023 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ã߰迬¼ö°Á : 2023-09-09
±³À°ÀÏÀÚ : 2023-09-09
±³À°Àå¼Ò : ¼¿ï´ëÇб³ ¾Ï¿¬±¸¼Ò ÀÌ°ÇÈñȦ
±³À°ÁÖÁ¦ : 2023 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ã߰迬¼ö°ÁÂ
ÁÖÃÖ±â°ü : ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : kspho@kams.or.kr
±³À°Á¾·ù : ¼Ò¾Æû¼Ò³â°ú
Âü¼®¿¹»óÀÎ : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Àü¹®ÀÇ 50,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 10:30~11:00 Overview of clinical trial ÀÌÁö¿ø(¼º±Õ°üÀÇ)
±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 11:00~11:30 Endpoints in clinical trial ÃÖÁ¤À±(¼¿ïÀÇ´ë )
±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 11:30~12:00 Statistical design Á¤Àΰæ(¿¬¼¼ÀÇ´ë )
±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 13:00~13:40 È¿À²ÀûÀÎ eCRFÀÇ °³¹ß ÀÓ´ö»ó(CRScube COO)
±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 14:00~14:30 Chemotherapy induced common toxicity evaluation and management ¾çÀ¯Áø(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 14:30~15:00 Developmental issues for pediatric cancer clinical trial ±èÇý¸®(¿ï»êÀÇ´ë )
±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 15:00~15:30 Immune related toxicity management ÃÖ¿µ¹è(¾ÆÁÖÀÇ´ë )
±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 15:50~16:20 Reporting AE/SAE/SUSAR to IRB, sponsors and MFDS ³ª¼±¿µ(»ï¼º ACRO )
±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 16:20~16:50 Monitoring and Audit ³ª¼±¿µ(»ï¼º ACRO )
±³À°½Ã°£ 09¿ù 09ÀÏ ÀÌ°ÇÈñȦ 16:50~17:20 How to get the approval of HIRA clinical trial reimbursement program ½ÅÇöÁ¤(»ï¼º ACRO )